Efalizumab: results of a 3-year continuous dosing study for the long-term control of psoriasis

BACKGROUND: Efalizumab, a T-cell-targeted, recombinant, humanized, monoclonal IgG1 antibody, inhibits key T-cell-mediated steps in the pathogenesis of psoriasis. Efalizumab is approved for the treatment of moderate-to-severe chronic plaque psoriasis in adults in more than 50 countries. OBJECTIVES: T...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Leonardi, C, Menter, A, Hamilton, T, Caro, I, Xing, B, Gottlieb, AB
Format: Artigo
Idioma:Inglês
Publicat: Blackwell Publishing Ltd 2008
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2408637/
https://ncbi.nlm.nih.gov/pubmed/18373710
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2133.2008.08548.x
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars